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Cerebral ischemia associated with PercuSurge
balloon occlusion balloon during carotid stenting:
Incidence and possible mechanisms
Rabih A. Chaer, MD, Susan Trocciola, MD, Brian DeRubertis, MD, Stephanie C. Lin, MD, K. Craig
Kent, MD, and Peter L. Faries, MD, New York, NY
Background: Interruption of antegrade cerebral perfusion results in transient neurologic intolerance in some patients
undergoing carotid angioplasty and stenting (CAS). This study sought to evaluate factors that contributed to the
development of cerebral ischemia during PercuSurge balloon occlusion and techniques used to allow successful
completion of the CAS procedure.
Methods:The PercuSurge occlusion balloonwas used in 43 of 165 patients treated with CAS for high-grade stenosis (mean
stenosis, 90%). All 43 patients were at increased risk for endarterectomy (7 restenosis, 3 irradiation, 3 contralateral
occlusion, and 30 Goldman class II-III); 20% were symptomatic. Symptoms of cerebral hypoperfusion during temporary
occlusion of the internal carotid artery occurred in 10 of 43 and included dysarthria (7/10), agitation (6/10), decreased
level of consciousness (5/10), and focal hemispheric deficit (3/10). An incomplete circle of Willis or contralateral carotid
artery occlusion, or both, was present in 8 of 10 patients. Symptoms resulting from PercuSurge balloon occlusion were
managed by balloon deflation with or without evacuation of blood from the internal carotid artery using the Export
catheter. All symptoms resolved completely without deficit after deflation of the occlusion balloon.
Results: The development of neurologic symptoms after initial PercuSurge balloon inflation and occluded internal carotid
artery flow was associated with a decrease in the mean Glasgow Coma Scale (GCS) from 15 to 10 (range, 9 to 14); the
GCS returned to normal after occlusion balloon deflation and remained normal during subsequent reinflation. The mean
time to spontaneous recovery of full neurologic function was 8 minutes (range, 4 to 15 minutes). No thrombotic or
embolic events were present on cerebral angiography or computed tomography scan. Balloon reinflation was performed
after a mean reperfusion interval of 10 minutes after full neurologic recovery (range, 4 to 20 minutes). The mean
subsequent procedure duration was 11.9 minutes (range, 6 to 21 minutes). No recurrence of neurologic symptoms
occurred when the occlusion balloon was reinflated. All 10 patients underwent successful CAS without occlusion,
dissection, cerebrovascular accident, or death.
Conclusion: Several factors may contribute to the development of neurologic intolerance during CAS with balloon
occlusion. Elucidation of the protective cellular mechanisms that invoke ischemic tolerance after the initial transient
ischemic event may enable CAS with embolic protection in patients who cannot tolerate initial interruption of antegrade
cerebral perfusion. (J Vasc Surg 2006;43:946-52.)The advent of carotid angioplasty and stenting (CAS)
has been predicated upon achieving low periprocedural
cerebrovascular accident rates that are equal to that of
carotid endarterectomy.1,2 The development of cerebral
protection devices is believed to be integral to achieving
acceptable periprocedural rates of cerebrovascular accident
during CAS.3-9 Cerebral protection devices are deployed in
the internal carotid artery distal the index lesion. They are
designed to prevent embolization of atheromatous debris
that may be dislodged during CAS and thereby prevent
periprocedural cerebrovascular accident.
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946Two techniques are currently being used in the
United States: filter devices and temporary balloon oc-
clusion.10 Filter-based cerebral protection devices main-
tain antegrade cerebral blood flow in the ipsilateral in-
ternal carotid artery during the CAS procedure, and
occlusion balloons require the temporary interruption of
flow. A third technique used for embolic protection
outside the United States uses reversal of flow in the
internal carotid artery.11
The interruption of antegrade cerebral perfusion may
induce cerebral ischemia. In 9% to 19%of patients undergoing
carotid endarterectomy, manifestations of cerebral ischemia
develop that necessitate placement of a temporary intravascu-
lar shunt to maintain antegrade cerebral perfusion.12-14 This
number increases considerably when occlusion of the con-
tralateral internal carotid artery is present; and up to 39% of
patients with contralateral carotid occlusion require shunt
placement during carotid endarterectomy.15,16 Transient
neurologic intolerance resulting fromballoon occlusion of the
internal carotid artery during CAS has also been reported. 10
This study sought to evaluate factors that contributed
to the development of cerebral ischemia during PercuSurge
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completion of the CAS procedure.
METHODS
Demographics. From January 2003 to January 2005,
165 patients (87 men, 13 women) with carotid artery
stenosis were treated with CAS. Prospective data collection
was performed under the approval of the institutional re-
view board. All patients and procedures were entered pro-
spectively into a computerized vascular registry. Data relat-
ing to the periprocedural events, including transient
ischemic attacks, were entered prospectively in the database
and were retrospectively analyzed.
Procedural details recorded included heart rate, blood
pressure, medications given, degree of stenosis, size of
native vessel, side of procedure, stent type and size, protec-
tion device used, and angioplasty balloon size. Postopera-
tive data collected included heart rate, blood pressure,
medications, cardiac enzymes, electrocardiogram changes,
morbidity, mortality, and length of stay.
The PercuSurge occlusion balloon (Medtronic, Santa
Rosa, Calif) was used in 43 of 165 patients treated with
CAS for high-grade stenosis. Fifteen patients were treated
under the MavericII (Medtronic Inc., Minneapolis, MN)
study protocol. The indications for using the occlusion
balloon in the remaining patients included significant ca-
rotid tortuosity, heavily calcified high-grade lesions, and
failure of delivery of a filter wire.
All 43 patients were at increased risk for endarterec-
tomy: 7 (16.3%) had restenosis, 3 (7%) had irradiation, 3
(7%) had contralateral occlusion, and 30 (70%) were Gold-
man class II-III. Significant coronary artery disease was
present in 27 patients (63%) as determined preoperatively
by myocardial stress testing or cardiac catheterization, and
three (7%) had severe chronic obstructive pulmonary dis-
ease prohibiting intubation and administration of general
anesthesia.
The mean age of patients treated in the study was 75.9
years (range, 67 to 93 years). The degree of carotid stenosis
was 80% in all cases, with a mean stenosis of 90% (range,
80% to 99%) as determined on angiographic imaging using
the distal internal carotid artery as reference. Of the patients
treated using the PercuSurge balloon, 20% were symptom-
atic from the carotid stenosis, and 80% were asymptomatic.
Asymptomatic patients were treated only in the presence of
a 80% stenosis.
Carotid angioplasty and stenting technique. All pa-
tients underwent CAS under local anesthesia, without se-
dation. Procedures were performed by vascular surgeons in
the operating room angiography suite using a fixed-
imaging system (Siemens AG,Munich, Germany). Femoral
access was used in all cases. Cerebral protection devices
were used in 162 of 165 cases, excluding three patients who
had restenosis after carotid endarterectomy (n 2) or CAS
(n  1). Microporous filters were used in 119 patients and
included EPI FilterWire (Boston Scientific, Natick, Mass),
Accunet (Guidant, Minneapolis, Minn), and Angioguard
(Cordis, Warren, NJ). Prophylactic atropine (0.5 to 1.0mg) was administered before simulation of the carotid
baroreceptor by angioplasty balloon inflation. After the
resultant increase in heart rate was observed, the lesion was
predilated with a 4 40 mmmonorail angioplasty balloon
(Long VIVA, Boston Scientific). This balloon length was
used to ensure adequate coverage of the target lesion.
A self-expanding stent was then deployed across the
lesion. Types of stents used included Wallstent (Boston
Scientific), AVE carotid stent (Medtronic), Acculink
(Guidant), Precise (Cordis), and NexStent (Endotex, Cu-
pertino, Calif). Postdilatation with a monorail balloon (5
20 mm to 6  20 mm) (Gazelle, Boston Scientific) was
performed. A short balloon was used in order to remain
within the boundaries of the stent. Nitroglycerin (100 to
300 g) was administered for treatment of spasm of the
distal internal carotid artery in six cases and was not associ-
ated with hypotension or vasopressor use. The PercuSurge
occlusion balloon was used in 43 patients treated with CAS
for high-grade stenosis.
Cerebral protection. The PercuSurge balloon was ad-
vanced across the index lesion. The system is designed to
contain and aspirate embolic material (thrombi and debris)
while performing percutaneous transluminal angioplasty
(PTA) and stenting procedures. The PercuSurge has an
inflation device that can be set to inflate the occlusion
balloon to between 3 and 6 mm by 0.5-mm increments.
The inflated balloon is positioned at least 3 cm distal to the
stenosis to prevent interference with the distal tip of the
self-expanding stent delivery system. Use of an additional
0.014-inch guidewire to provide additional support (buddy
wire) was required to permit passage of the PercuSurge wire
in five patients with extensive tortuousity of the internal
carotid artery. Dilatation of the carotid stenosis was not
required prior to advancing the PercuSurge wire in any
case.
Once positioned in a straight portion of the internal
carotid artery, the PercuSurge balloon was inflated to a
diameter of 5 to 6 mm. Angiography was performed to
confirm temporary occlusion of flow in the internal carotid
artery. The PercuSurge system was used in five patients
after failure of delivery of a filter wire cerebral protection
device in heavily calcified high-grade lesions.
Pharmacologic measures. All patients received 75
mg of clopidogrel (Sanofi-Synthelabo Pharmaceuticals,
New York, NY) daily for 5 days before the initiation of the
CAS procedure and were maintained on clopidogrel for at
least 30 days postoperatively. All medications, including
antihypertensive medications, were continued through the
day of surgery. Anticoagulation with heparin sodium was
maintained throughout the procedure, with a target acti-
vated clotting time of 250 to 350 seconds. Atropine (0.5 to
1.5 mg) was given prophylactically before balloon dilata-
tion for the treatment of reflex bradycardia associated with
dilatation of the carotid baroreceptor. Intravenous vasoac-
tive agents were used for management of hypotension
(systolic BP 90 mm Hg) in three cases involving the use
of the PercuSurge balloon. Dopamine was used as the
primary agent for hypotension; supplemental phenyleph-
Ev
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potension. In addition, fluid resuscitation was performed
for all patients who experienced hypotension.
Statistical analysis. Univariate testing was done using
Fisher’s exact test for analysis of dichotomous data and t
tests for continuous data analysis. Continuous data are
expressed as mean  standard deviation. Significance was
assumed at P  .05. Data were managed and analyzed by
SPSS 13 statistical software (SPSS Inc., Chicago, Ill).
RESULTS
Outcomes. The PercuSurge balloon was deployed
and CAS was performed successfully in all 43 patients. No
access vessels were dissected in any patient. There were no
instances of occlusion of the internal carotid or other
arteries. Hematoma at the access site occurred in two
patients but did not require blood transfusion. One pseu-
doaneurysm occurred at the femoral access site that re-
quired thrombin injection to correct. No patient required
intubation or mechanical ventilatory support, and all pa-
tients were transferred to a monitored stepdown bed post-
operatively. No transient ischemic attacks or ischemic sei-
zures occurred. A postoperative headache developed in one
patient, which was alleviated by blood pressure control.
There was no other clinical evidence of hyperperfusion
syndrome. There were no cerebral vascular accidents, myo-
cardial infarctions, and no 30-day mortality. The length of
stay was 1 to 5 days, with a mean of 1.33 days.
Transient neurologic intolerance. Manifestations of
neurologic intolerance occurred in 10 (23.3%) of 43 pa-
tients during PercuSurge balloon occlusion of antegrade
flow in the internal carotid artery. In all cases, these symp-
toms resolved completely and spontaneously after CAS
completion. Symptoms of cerebral ischemia in these pa-
tients were dysarthria in 7, decreased level of consciousness
in 5, and hemispheric neurologic deficit in 3. In addition,
six patients experienced altered mental status associated
with agitation.
The development of neurologic symptoms after initial
PercuSurge inflation was associated with a decrease in the
mean Glasgow Coma Scale (GCS) from an initial mean
score of 15 to a mean minimum score of 10 (minimum
score range, 9 to 14); GCS returned to 15 after balloon
deflation and subsequent reinflation. The mean time to
spontaneous recovery of full neurologic function was 8
minutes (range, 4 to 15 minutes).
No thrombotic or embolic events were present on
cerebral angiography, postoperative computed tomogra-
Precipitating factors and intervention for transient neurolo
Precipitating factor Patients
Initial PercuSurge 5
Dilatation of carotid baroreceptor 3
Cumulative cerebral ischemia 2phy (2 patients), or magnetic resonance imaging (4 pa-tients). In addition, there was no significant difference in
the proportion of patients in whom macroscopic embolic
debris was recovered from the aspiration catheter.
Precipitating factors. The development of cerebral
ischemia with manifestations of transient neurologic intol-
erance was associated with distinct aspects of the CAS
procedure in 10 patients (Table). In five patients, this factor
was the initial occlusion of the internal carotid by inflation
of the PercuSurge balloon. There were no simultaneous
associated hemodynamic changes, with a mean systolic
blood pressure of 139 mmHg (range, 115 to 166 mmHg)
and a mean heart rate of 80 beats/min (range, 66 to 94
beats/minutes). The blood pressure and heart rate re-
corded during the period of neurologic intolerance were
similar to the values recorded at the start of the procedure
(P  NS).
Neurologic intolerance developed with stimulation of
the carotid baroreceptor during transluminal dilatation of
the carotid stenosis in three patients. Neurologic intoler-
ance was precipitated by the development of bradycardia to
a heart rate of50 beats/min and hypotension to a systolic
blood pressure of 80 mm Hg in these three patients.
Symptoms developed in one patient during predilatation
using the 4  40 mm angioplasty balloon, and symptoms
developed in two during postdilatation with the 5.5  20
mm angioplasty balloon. Transient neurologic intolerance
developed in two patients in a delayed fashion, 8 to 14
minutes after the initial PercuSurge balloon occlusion of
the internal carotid artery. Neurologic intolerance in these
instances appeared to result from the cumulative effects of
cerebral ischemia and was not clearly attributable to a
specific procedural factor or event.
Intracranial collateral circulation. Incomplete col-
lateral circulation to the cerebral hemisphere ipsilateral to
the index carotid artery was present in most of the patients
in whom transient neurologic intolerance developed dur-
ing occlusion of the carotid artery. An incomplete circle of
Willis or contralateral carotid artery occlusion, or both, was
present in 8 of 10 patients. Of patients who experienced
transient neurologic intolerance, 54% exhibited absence of
the anterior communicating artery, the posterior commu-
nicating artery, or both. However, incomplete intracranial
collateral arteries (anterior communicating, posterior com-
municating or both) were also demonstrated in 39% of
patients who did not experience neurologic intolerance.
This difference failed to achieve statistical significance (P
NS). Of note, occlusion of the contralateral internal carotid
artery was observed in three patients in the study, and
tolerance
Treatment
acuation and PercuSurge deflation balloon occlusion
travenous vasopressors and auto cardiac compression; evacuation
and PercuSurge deflation
acuation and PercuSurge deflationgic in
Ev
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occlusion by inflation of the PercuSurge balloon did not
correlate with the development of neurologic intolerance
(P  NS).
Management of neurologic intolerance. Several
techniques were used to manage the development of neu-
rologic intolerance and allow completion of the CAS pro-
cedure.
Immediate intolerance to initial PercuSurge balloon
inflation occurred in five patients, and the occlusion bal-
loon was rapidly deflated. Symptoms resolved completely
without permanent neurologic deficit in all cases. Once
neurologic function returned to normal, the occlusion
balloon was reinflated and the CAS procedure was com-
pleted. PercuSurge balloon reinflation was performed after
a mean reperfusion interval of 10 minutes after full neuro-
logic recovery (range, 4 to 20 minutes). The mean subse-
quent procedure duration was 11.9 minutes (range, 6 to 21
minutes). No neurologic symptoms recurred after reinfla-
tion of the occlusion balloon.
In the three patients in whom neurologic intolerance
was precipitated by stimulation of the carotid baroreceptor
by balloon dilatation, intravenous vasopressors were ad-
ministered to alleviate hypotension. Vasopressor support
with dopamine was used in all three patients. Supplemental
phenylephrine was administered in one patient and norepi-
nephrine was used in one other for refractory hypotension.
Complete asystole developed in two of these patients as a
result of carotid balloon dilatation. These patients were
instructed to cough forcefully to provide autocardiac com-
pression. Forceful coughing resulted in generation of sys-
tolic pressures up to 60 mm Hg in these patients. No
syncope developed in these two patients, and they were
instructed to discontinue coughing after spontaneous res-
toration of a normal sinus rhythm. The development of
bradycardia with a heart rate of 50 beats/min was signif-
icantly reduced by the routine administration of atropine
before the initial dilatation within the carotid bulb.
All patients, including the two patients who developed
cumulative ischemia developed without an evident precip-
itating factor, were managed by evacuation of the blood
and any particulate matter from the internal carotid artery.
Aspiration and PercuSurge balloon deflation was only used
in patients whose neurologic intolerance persisted after the
restoration of sinus rhythm and normotension. This al-
lowed for subsequent deflation of the PercuSurge occlusion
balloon and restoration of antegrade cerebral perfusion.
Once neurologic function returned to normal, the occlu-
sion balloon was reinflated and the CAS procedure was
completed. The mean subsequent procedure duration in
these five patients was 7.9 minutes (range, 5 to 9 minutes).
There was no significant difference between the blood
pressure and heart rate recorded after the second inflation
of the PercuSurge balloon and the hemodynamic parame-
ters recorded at the outset of the procedure (P  NS).
Again, no recurrence of cerebral ischemia or neurologic
intolerance occurred, suggesting the induction of neuro-
logic tolerance by ischemic preconditioning. All 10 patientsunderwent successful dilatation of their carotid stenoses
without occlusion, dissection, cerebrovascular accident, or
cerebral hemorrhage.
Follow-up. During the 6- to 24-month follow-up
period (mean, 15 months), none of the patients have
developed hemodynamically significant restenosis of the
treated carotid artery. No patient has required reinterven-
tion on the index carotid artery. In addition, no patient has
developed progression of disease in the contralateral ca-
rotid artery that required intervention. No delayed neuro-
logic events (cerebrovascular accident, transient ischemic
attack, or any other neurologic deficit) have occurred in the
patients treated in the study. Hemodynamically significant
stenosis of the external carotid artery has occurred in three
patients—but no instances of external carotid artery occlu-
sion—and no further interventions have been undertaken.
These patients have remained free of clinical manifestations
of the external carotid stenosis. No patients died.
DISCUSSION
Cerebral ischemia during temporary occlusion of the
internal carotid artery develops in a significant proportion
of patients during the performance of carotid endarterec-
tomy.11-16 This is generally well tolerated and does not
inevitably lead to the development of cerebral infarction.
The reported experience with CAS using the PercuSurge
balloon has been more limited,17-19 however, and the
associated cerebral hypoxia has not been fully character-
ized.
Ischemic preconditioning is an endogenous cellular
protective mechanism whereby brief, noninjurious periods
of ischemia render a tissue more resistant to a subsequent,
more prolonged ischemic insult. Its protective effect has
been initially described in the myocardium20-26 and has
also been described in animal models in which transient
spinal cord ischemia reduces neurologic injury after exper-
imental aortic occlusion.27-28 This neuroprotective effect
has also been described in a murine model of both global
and focal cerebral ischemia and is demonstrated acutely
after a very short 3-minute initial sublethal insult that is
followed by 30 minutes of reperfusion.29-33 The exact
mechanism by which the ischemic preconditioning effect is
mediated remains unknown but is believed to involve sev-
eral mediators such as adenosine, nitric oxide, and upregu-
lation of inducible nitric oxide synthase.27,34-38
Although evidence from clinical trials published in the
cardiac literature suggests that ischemic preconditioning
occurs in humans,20-25 the evidence for ischemic precon-
ditioning in the human brain is less firm. Some studies
suggest that patients with stroke who had a prior transient
ischemic attack have milder neurologic deficits at presenta-
tion and a better functional recovery,39-40 although the
mechanisms at play remain controversial.39
Of considerable interest was the occurrence of neuro-
logic intolerance immediately upon the initial inflation of
the occlusion balloon in the internal carotid artery. This
immediate onset of cerebral ischemia occurred in five pa-
tients and was alleviated by deflation of the PercuSurge
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The cerebral ischemia induced by the initial balloon occlu-
sion appeared to induce ischemic preconditioning, since
reinflation and reocclusion of the internal carotid artery did
not induce any further manifestations of neurologic intol-
erance. However, improvement of collateral flow after fluid
resuscitation and reversal of hemodynamic instability that
occurred in some patients during the neurologic event
likely also contributed to the subsequent tolerance to bal-
loon reinflation. Agitation was the first sign of neurologic
intolerance in six patients after interruption of antegrade
carotid perfusion, which subsequently resolved with the
reinflation of the PercuSurge occlusion balloon and correc-
tion of hypotension.
Nomeasurements of cerebral perfusion such as electro-
encephalography (EEG) or sensory evoked potentials were
obtained in this study; therefore, it is not possible to
completely characterize the mechanisms occurring in the
adult brain that lead to ischemic preconditioning. Physio-
logic monitoring during CAS may allow the prediction of
ischemic preconditioning in patients undergoing complete
interruption of unilateral antegrade cerebral blood flow.
Although positron emission tomography (PET) scanning is
an attractive tool to evaluate functional changes in cerebral
activity, it is not possible to obtain intraoperatively during
CAS.
Other potential tests include intraoperative transcranial
Doppler monitoring that may reveal a change in regional
cerebral blood flow in patients experiencing ischemic pre-
conditioning after transient occlusion of their internal ca-
rotid artery. However, cerebral blood flow, as measured by
laser-Doppler flowmetry, did not differ during occlusion
and reperfusion in a murine model of preconditioning
despite reduction in infarct size in the preconditioned
group.35 The lack of transcranial Doppler monitoring in
this study precluded any hemodynamic assessment during
the procedure as well as any description of the number of
hits potentially generated with the use of the PercuSurge
occlusion balloon. EEG monitoring with evaluation of
frequency delays during periods of cerebral hypoxia could
also be used. EEG changes associated with ischemic pre-
conditioning are not fully characterized, but can be inferred
by the improvement of depolarization activity associated
with cerebral hypoxia.
In three of the 10 patients, the onset of cerebral isch-
emia resulting in neurologic intolerance was directly asso-
ciated with bradycardia and hypotension that resulted from
balloon dilatation of the carotid sinus baroreceptor. Early
in the study period, atropine was administered selectively
for the development of bradycardia and hypotension. With
increased experience, however, routine prophylactic ad-
ministration was initiated for all patients with primary ca-
rotid lesions before angioplasty of the carotid bulb.41
Previous angiographic studies of the intracranial circu-
lation have indicated that the need for an intravascular
shunt may be predicted from the status of the collateral
circulation to the hemisphere ipsilateral to the index carotid
stenosis.42 In the current study, 40% of the patients whodeveloped neurologic intolerance had incomplete intracra-
nial collateral vessels, that is, an absent anterior or posterior
communicating artery. Interestingly, incomplete intracra-
nial collaterals were present in 39% of patients who did not
experience neurologic intolerance. As a likely result of the
relatively small sample size, these figures did not achieve
statistical significance.
Although it seems intuitively likely that incomplete
collateral arterial communication may contribute to the
development of neurologic intolerance during CAS using
the PercuSurge balloon, the results of the current study are
not able to confirm this supposition. Ischemic precondi-
tioning could, however, be potentially used prophylacti-
cally in patients with an incomplete circle of Willis who
require CAS with interruption of antegrade cerebral perfu-
sion, especially patients with an absent anterior communi-
cating artery who likely have significantly compromised
collateral cerebral circulation.
The duration of PercuSurge occlusion balloon inflation
did not correlate with the development of cerebral ischemia
and neurologic intolerance. The average duration of bal-
loon occlusion of the internal carotid artery was relatively
limited at 11.9 minutes, and the maximum duration was 21
minutes. These durations are shorter than the time typically
reported for performance of carotid endarterectomy. De-
spite this, the incidence of neurologic intolerance was rel-
atively high in the current study. Of additional potential
significance is the finding that two of the three patients with
occlusion of the contralateral internal carotid artery did
develop neurologic intolerance. The combination of con-
tralateral carotid occlusion in one third of the patients, in
which setting the expected needed rate of shunting is as
high as 39%,15,16 and hypotension and bradycardia in 5
additional patients, may therefore explain the higher inci-
dence of neurologic intolerance observed in this study.
The etiology of cerebral ischemia resulting in neuro-
logic intolerance during CAS with the PercuSurge balloon
appears to be multifactorial. Incomplete collateral circula-
tion or occlusion of the contralateral internal carotid artery
may be contributing factors as well as hemodynamic insta-
bility resulting from angioplasty of the carotid bulb. Al-
though balloon occlusion time did not correlate directly
with the development of neurologic intolerance, it has the
potential to be one of the multifactorial elements contrib-
uting to neurologic intolerance. Consideration of these
factors during the performance of CAS with the Percu-
Surge occlusion balloon for cerebral protection is prudent.
The avoidance of hypotension and asystole by routine
atropine pretreatment before angioplasty and the ready
availability of intravenous vasopressors for administration
are two factors that may be directly controlled. Limiting
balloon inflation time to the extent possible is also likely to
be worthwhile. The status of the contralateral carotid artery
and the anterior and posterior communicating arteries,
although not modifiable, may identify patients at high risk
for developing neurologic intolerance following interrup-
tion of antegrade carotid perfusion.
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Several factors may contribute to the development of
neurologic intolerance during CAS with balloon occlusion.
Elucidation of the protective cellular mechanisms that in-
voke ischemic tolerance after the initial transient ischemic
event may enable CAS with embolic protection in patients
who cannot tolerate the initial interruption of antegrade
cerebral perfusion by PercuSurge occlusion.
As such, interventions based on the mechanisms of
ischemic tolerance could be used in preventive or treatment
strategies. Although not characterized at the molecular
level in patients undergoing CAS, the potential benefit of
ischemic tolerance induced by PercuSurge balloon occlu-
sion makes this cerebral protection device a valuable tool in
the armamentarium of carotid artery angioplasty and stent-
ing.
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Dr Juan Parodi (St. Louis, Mo). This is a very interesting
paper, no question about it. I have a question. The incidence of
intolerance is about 25%, and in most of the cases, occluding the
carotid artery in all the reports the incidence is about 5%. How do
explain that? In a few cases you have hypotension, but what about
in the delay Intolerance? Were those patients hypotensive, because
25% is too high for that.
Dr Rabih Chaer. The only hypotensive patients were those
three patients that became hypotensive secondary to bradycardia
associated with inflation of the predilatation or postdilatation
balloon. It is true that the incidence of neurologic intolerance was
around 4% to 5% in the largest PercuSurge trial. However, Cremo-
nesi et al have reported an incidence of up to 15% with PercuSurge,
6 out of 40 patients, in Stroke in 2003. I think that the true
incidence of neurologic intolerance that can be attributed to
PercuSurge alone is probably around 15% to 20%, excluding those
patients that had bradycardia and hypotension. This may be attrib-
uted to the fact that more high-risk symptomatic patients with
contralateral disease and more challenging anatomy are being
treated.
Dr. Parodi. The other comment is the following: Dr Enrique
Criado did a study of oxygen extraction comparing occlusion and
flow reversal, because initially we thought that flow reversal was
worse than occlusion since in addition to the occlusion we were
stealing blood from the brain. What he found was that oxygen
extraction with occlusion was much higher than with flow reversal.
That means that the ischemia produced by occlusion with the
PercuSurge was more important than the ischemia produced by
flow reversal apparently because flow reversal opened collaterals.
This is a very interesting paper and is coincident with our findingsflated the balloon and the second inflation was tolerated much
better than the initial one.
Dr Robert Molnar (Flint, Mich). Just one quick question. In
our experience with the PercuSurge device in patients that didn’t
tolerate it, we did a similar technique in which we staged the
procedure so inflation of the balloon, place the stent, do an
aspiration, let the balloon down, rescue them for a little bit,
balloon goes back up, postdilatation, etc. Did you do that at all
during this series or was it strictly preconditioning? Can you just go
over again the time frame that that preconditioning was done?
How long was preconditioning done to achieve that effect?
Dr Chaer. In three patients, the intolerance occurred within
60 seconds of inflation of the PercuSurge, and in the other pa-
tients, it happened later on during the procedure. The algorithm
you described is very similar to our approach—stabilizing the
patient, giving atropine, fluid, and vasopressors, if needed, aspirat-
ing the stagnant column of blood with the Export catheter, and
obtaining an angiogram before and after deflating the PercuSurge
balloon, including intracerebral projections. If there was no reason
to suspect that there is an ongoing neurologic deficit, then you are
at the point where you have to complete the procedure.
We attempted reinflating the PercuSurge balloon and all pa-
tients that had an initial neurologic event tolerated balloon rein-
flation. Then we looked back trying to explain these findings,
knowing that the concept of ischemic preconditioning has been
fairly well established in the cardiac literature. Although this is not
as well characterized in the human central nervous system, I think
that ischemic preconditioning induces neurologic tolerance during
carotid angioplasty and stenting that may allow you to complete
the procedure following the initial neurologic intolerance.
